Skip to main content

Article Category

News

Article available in the folowing languages:

PLANTON receives BioChancePlus research funding

The PLANTON GmbH, Kiel was able to allocate subsidies of approximately 1 Million Euro in the course of the German Federal Ministry of Education and Research (BMBF) BioChancePlus program.

The biotech company from Kiel receives the funding for the production and further development of a new anti-microbial component in plants (Plant Made Pharmaceuticals). PLANTON specializes in antibiotic substances that are produced by human skin to defend against infections. Due to their broad anti-microbial spectrum and the high efficiency against bacterial, viral and fungal infections these substances carry an extremely high therapeutic potential as innovative antibiotics. In order to facilitate the molecule production in industrial scale for research purposes and the subsequent drug development, PLANTON uses a unique technique: the substances are produced in especially developed plants, e.g. potatoes which are used as bioreactors. For the preclinical and clinical development phases it is necessary to adjust and further develop the existing technology. For this purpose, PLANTON has been granted the subsidies from the BMBF program BioChancePlus. BioChancePlus supports industrial research and early-stage development projects from the field of modern biotechnology. Only projects with a technologically high level and with good chances of success in the market are being supported. Further information: PLANTON GmbH Dr. Michael Kleine Tel: +49 (0)431 38015 0 Fax: +49 (0)431 38015 11 Email: info@planton.de Url: http://www.planton.de

Countries

Germany